Cele(rino) Abad-Zapatero

Current

• Visiting Scientist at EMBL-EBI
• Adjunct Professor at University of Illinois at Chicago

Past

• Associate Research Fellow. Group Leader at Abbott Laboratories

Education

• The University of Texas at Austin

Connections

43 connections

Industry

Pharmaceuticals

Websites

• UIC CPB website

Cele(rino) Abad-Zapatero’s Summary

After more than twenty two years in the pharmaceutical industry using the
concepts and methods of Structure-Based Drug Discovery, I have to come
to realize its power and its limitations. Moreover, I think that the complete
emphasis on the potency of compounds towards their targets as the driving
force in drug discovery has serious limitations. The complexity of the drug-discovery field requires the development of more inteligent variables that will
provide a deeper insight into the drug discovery process and that can help us devise better ways to drive drug-discovery through the 21st century. I want to develop better ways to direct drug discovery by using other variables than the standard Ki between the compound and the target. In particular, I believe that Ligand Efficiency Indices (LEIs) can play critical role as 'figures of merit' to drive drug discovery.
==
As a science communicator, I believe that one of the ways to approach the lay public to explain scientific ideas and concepts is by connecting with the world of the arts. We
have to convey to the non-scientist that the arts and the sciences are both parts of the human culture. We have to use this connection to reach the public who in the end will benefit from researchs in all areas of enquiry.

Cele(rino) Abad-Zapatero’s Specialties:

Structure Based Drug Discovery
Fragment-Based Drug Discovery
Screening by Crystallography
Macromolecular Crystallography
Ligand Efficiency Indices applied to drug discovery

Cele(rino) Abad-Zapatero’s Experience

• Visiting Scientist

  EMBL-EBI

  (Non-Profit; Non-Profit Organization Management industry)

  September 2009 — Present (4 months)

  Spending a two month period at the EBML-EBI group in
  Hinxton, Cambridge, UK to work on a application of LEIs to
  databases and drug discovery.

• Adjunct Professor

  University of Illinois at Chicago

  (Educational Institution; Pharmaceuticals industry)

  March 2007 — Present (2 years 10 months)

  Adjunct Professor at the Center for Pharmaceutical Biotechnology.
  Developing computational methods to direct drug discovery using
  the concepts of Ligand Efficiency Indices (LEIs).
  
  Member of the NASW. Writing essays, plays, books, newspaper articles and columns (English, Spanish) with the goal of communicating Science to the lay public and society at large. The Sciences and the Arts are similar endeavors of the creative energy of the human spirit and both should be considered part of the culture of the nations and of humankind.

• Associate Research Fellow. Group Leader

  Abbott Laboratories

  (Public Company; 10,001 or more employees; ABT; Pharmaceuticals industry)

  April 1985 — February 2008 (22 years 11 months)

  Initiated, developed and estrablished SBDD at Abbott Laboratories
  including the formation of the IMCA consortium from its inception.

Cele(rino) Abad-Zapatero’s Education

• The University of Texas at Austin

  1972 — 1978

Additional Information

Cele(rino) Abad-Zapatero’s Websites:

• UIC CPB website

Cele(rino) Abad-Zapatero’s Interests:

Development of computational and experimental methods to make drug discovery more effective. Science communication by any media: essays, books, plays, documentaries.

Cele(rino) Abad-Zapatero’s Groups:

American Crystallographic Association, American Chemical Society, Biophysical Society, AAAS

•    Biotech & Pharma Professionals Network
•    Science & Technology Media Professionals™
•    Fragment-based Drug Discovery
•    Medicinal Chemistry and Drug Discovery

Cele(rino) Abad-Zapatero’s Contact Settings

Interested In:

• career opportunities
• consulting offers
• new ventures
• job inquiries
• expertise requests
• business deals
• reference requests
• getting back in touch